Match tier
Listed
Presence
Current · Arkansas
Last published
2025
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
P
Parth M. Dhamelia
Role not yet determined Is this you? Add your title
Also affiliated: Maulana Azad Medical College (2025); Mayo Clinic in Florida (2025)
1 h-index
6 pubs
5 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
Metrics
- h-index: 1
- Publications: 6
- Citations: 5
Selected Publications
-
Association Between Continuous Glucose Monitoring - Derived Time in Range and Diabetic Kidney Disease: A Systematic Review and Meta-Analysis of current evidence (2026)
-
Geographic Disparities in Access to CKD Randomized Clinical Trials in the United States. (2026)
-
Cardiac Allograft Immunoprotection in Combined Heart-Liver Transplantation: Mechanisms and Clinical Translation for the Sensitized Candidate (2026)
-
GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease (2026)
-
Hydrocortisone Use for Septic Shock in Patients With CKD (2026)
-
Treatment Challenges in a Complex Presentation of Diabetic Ketoacidosis, Hyperosmolar Hyperglycemic Syndrome and Hypernatremia: A Case Report (2026)
-
Patterns of cause of death among patients with subsequent primary malignancies after cutaneous melanoma: A SEER-based analysis (2000–2022). (2026)
-
Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease. (2026)
-
Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC. (2026)
-
Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases. (2026)
-
Fungal DNA in Circulation (2025)
Collaboration Network
Top Collaborators
Nishank Jain
University of Arkansas for Medical Sciences
5 shared publications
In database
- GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease
- Fungal DNA in Circulation
- Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.
- Hydrocortisone Use for Septic Shock in Patients With CKD
- Geographic Disparities in Access to CKD Randomized Clinical Trials in the United States.
Atulya Aman Khosla
Beaumont Hospital, Royal Oak (US)
4 shared publications
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
- Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
- Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.
- Patterns of cause of death among patients with subsequent primary malignancies after cutaneous melanoma: A SEER-based analysis (2000–2022).
Manas Vaibhav Pustake
Texas Tech University (US)
4 shared publications
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
- Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
- Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.
- Patterns of cause of death among patients with subsequent primary malignancies after cutaneous melanoma: A SEER-based analysis (2000–2022).
Mohammad Arfat Ganiyani
Baptist Hospital of Miami (US)
4 shared publications
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
- Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
- Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.
- Patterns of cause of death among patients with subsequent primary malignancies after cutaneous melanoma: A SEER-based analysis (2000–2022).
Yagnapriya Ammakola
3 shared publications
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
- Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
- Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.
Nitya Batra
Jacksonville College (US)
3 shared publications
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
- Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
- Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.
Karan Jatwani
George Washington University Hospital (US)
3 shared publications
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
- Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
- Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.
Rohan Garje
Miami Heart Research Institute (US)
3 shared publications
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
- Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease.
- Patterns of cause of death among patients with subsequent primary malignancies after cutaneous melanoma: A SEER-based analysis (2000–2022).
John M. Arthur
University of Arkansas for Medical Sciences
3 shared publications
In database
- GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease
- Hydrocortisone Use for Septic Shock in Patients With CKD
- Geographic Disparities in Access to CKD Randomized Clinical Trials in the United States.
Rohit Singh
University of Vermont Medical Center (US)
2 shared publications
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
- Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
Manmeet Singh Ahluwalia
Baptist Hospital of Miami (US)
2 shared publications
- Real-world outcomes of systemic therapy sequencing after earlier-generation EGFR TKI failure in NSCLC with brain metastases.
- Continued CNS-penetrant TKI therapy with or without local CNS therapy after brain metastasis diagnosis in NSCLC.
H Abeyagunawardene
University of Arkansas for Medical Sciences (US)
2 shared publications
- Hydrocortisone Use for Septic Shock in Patients With CKD
- Geographic Disparities in Access to CKD Randomized Clinical Trials in the United States.
Ninad Khandekar
Rochester General Hospital
2 shared publications
In database
- GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease
- Hydrocortisone Use for Septic Shock in Patients With CKD
Dharmik Jadvani
University of Arkansas for Medical Sciences
2 shared publications
In database
- GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease
- Geographic Disparities in Access to CKD Randomized Clinical Trials in the United States.
Siddharth Manish Lodha
Maulana Azad Medical College (IN)
2 shared publications
- Cardiac Allograft Immunoprotection in Combined Heart-Liver Transplantation: Mechanisms and Clinical Translation for the Sensitized Candidate
- Association Between Continuous Glucose Monitoring - Derived Time in Range and Diabetic Kidney Disease: A Systematic Review and Meta-Analysis of current evidence